Send me real-time posts from this site at my email

Watchlist Update: 12-24-2019 - HZNP - Horizon Therapeutics - Analyst Comments

$HZNP - On our trading list. A good longer term healthcare buy. very good performer this year!


Horizon Therapeutics analyst commentary at Piper Jaffray

Horizon Therapeutics price target raised to $49 from $36 at Piper Jaffray. Piper Jaffray analyst David Amsellem raised his price target for Horizon Therapeutics to $49 from $36 and reiterates an Overweight rating on the shares. The stock closed MOnday at $36.28. With Horizon "on the cusp of a seminal milestone" with the eventual approval of teprotumumab for thyroid eye disease, which offers a "relatively high probability of wide adoption," that there is "ample room for significant further value creation," Amsellem tells investors in a research note. The analyst says he's received favorable feedback on teprotumumab from past key opinion leader checks and a recent physician survey. He believes Horizon shares are well positioned for multiple expansion.


$HZNP, Horizon Therapeutics Public Limited Company / H1


Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue